title: Evaluation of thiophosphoric acid alkaloid derivatives from Chelidonium majus L. ("Ukrain") as an immunostimulant in patients with various carcinomas.
abstract: This paper summarizes the preliminary results of two independent clinical trials conducted with the preparation "Ukrain", containing thiophosphoric acid alkaloid derivatives from the plant Chelidonium majus L. (greater celandine), in order to investigate whether it has immunopotentiating properties in cancer patients. A total of twenty-seven patients with various malignancies were treated with "Ukrain" given intravenously in a dose of 10 mg every three days. In all patients the cellular and humoral immune response was studied. There was an increase in both total T-cells and T-helper lymphocytes, a decrease in T-suppressor cells, and normalization of the helper/suppressor (HIS) ratio. A significant increase in erythrocyte-rosette-forming T-cells and NK cells was also demonstrated. Serum immunoglobulin levels, complement components (C3 and C4), and acute phase proteins were not significantly enhanced. Restoration of cellular immunity was accompanied by an improvement in the patients' performance status and in the clinical course of the disease. The treatment was generally well tolerated. The present study shows that some therapeutic benefit from the use of Chelidonium majus ("Ukrain") as an immunostimulant in cancer patients can be achieved.
authors.affiliation: Ukrainian Anti-Cancer Institute, Vienna, Austria.
authors.forename: J W
authors.initials: JW
authors.lastname: Nowicky
authors.forename: A
authors.initials: A
authors.lastname: Staniszewski
authors.forename: W
authors.initials: W
authors.lastname: Zbroja-Sontag
authors.forename: B
authors.initials: B
authors.lastname: Slesak
authors.forename: W
authors.initials: W
authors.lastname: Nowicky
authors.forename: W
authors.initials: W
authors.lastname: Hiesmayr
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis; D000276:Adjuvants, Immunologic; D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology*; D001600:Berberine Alkaloids; D003165:Complement System Proteins / Q000032:analysis; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology*; D010617:Phenanthridines; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory
chemical_list: D000209:Acute-Phase Proteins; D000276:Adjuvants, Immunologic; D000470:Alkaloids; D001600:Berberine Alkaloids; D007136:Immunoglobulins; D010617:Phenanthridines; C060921:ukrain; D003165:Complement System Proteins